KR910005889A - 라임 질병에 대한 왁진 - Google Patents

라임 질병에 대한 왁진 Download PDF

Info

Publication number
KR910005889A
KR910005889A KR1019900014814A KR900014814A KR910005889A KR 910005889 A KR910005889 A KR 910005889A KR 1019900014814 A KR1019900014814 A KR 1019900014814A KR 900014814 A KR900014814 A KR 900014814A KR 910005889 A KR910005889 A KR 910005889A
Authority
KR
South Korea
Prior art keywords
antigen
borelri
bugs
monoclonal antibody
ospa
Prior art date
Application number
KR1019900014814A
Other languages
English (en)
Other versions
KR100205462B1 (ko
Inventor
엠. 지몬 마르쿠스
에. 샤이블레 울리히
아이히만 클라우스
크라머 미하엘
라인하르트 발리히
Original Assignee
원본미기재
막스-플랑크-게젤샤프트 쮸어 피르데롱 데어 비쎈샤프텐 에. 파우.
도이췌스 크랩브스포어승스첸트룸 스티프퉁 데스 외펜트리헨 레히츠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25885304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR910005889(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 원본미기재, 막스-플랑크-게젤샤프트 쮸어 피르데롱 데어 비쎈샤프텐 에. 파우., 도이췌스 크랩브스포어승스첸트룸 스티프퉁 데스 외펜트리헨 레히츠 filed Critical 원본미기재
Publication of KR910005889A publication Critical patent/KR910005889A/ko
Priority to KR1019980035375A priority Critical patent/KR100202128B1/ko
Application granted granted Critical
Publication of KR100205462B1 publication Critical patent/KR100205462B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

라임 질병에 대한 왁진
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도 보텔리아 버그도페리 ZS7로 부터의 31KD항원(SspA)의 DNA 및 아미노산 서열을 표시한다.
제2도는 재조합 단백질 rZS7/31-2의 면역학적 특성을 표시한다.

Claims (35)

  1. 보렐리아 버그도페리 (Borrelia bugdorferi)의 31KD 항원(OspA) 또는 34kD 항원(OspB)에 대해 특이적인 하나 이상의 단클론 항체를 함유한, 라인 질병에 대한 왁진.
  2. 제1항에 있어서, 항체가보렐리아 버그도페리균주 ZS7(DSM 5527) 및/또는 B31(ATCC 35210)의 31kD 또는 34kD항원에 대해 특이적인 왁진.
  3. 제1항 또는 제2항에 있어서, 활성 물질로서 IgG 형태의 단클론 항체를 함유하는 왁진.
  4. 제3항에 있어서, 활성 물질로서 아형IgG2b 또는 IgG1 형태의 단클론 항체를 함유하는 왁진.
  5. 전기한 항의 어느 한 항에 있어서, 살아있는 병원성보렐리아 버그도페리로 감염시킨 면역이 결핍된 실험용 동물에서 관절염, 심장염 및 간염의 발생을 예방하는 왁진.
  6. 전기한 항의 어느 한 항에 있어서, 살아있는보렐리아 버그도페리균주 ZS7로 감염시킨 면역이 결핍된 scid 생쥐에서 관절염, 심장염 및 간염의 발생을 실질적으로 예방하는 왁진.
  7. 보렐리아 버그도페리또는 이것의 부분으로 면역화된 실험용 동물의 임파구나 비장 세포로 부터 라임 질병에 대한 왁진을 얻는 방법에 있어서, 제1항 내지 제6항의 어느 한 항의 단클론 항체를 생산하는 하이브리도마가 임파구 또는 비장세포로 부터 세포 융합에 의해 얻어지는 방법.
  8. 제7항에 있어서, 실험용 동물이 생쥐인 방법.
  9. 제7항 또는 제8항에 있어서, 완전한보렐리아 버그도페리B31 및/또는 ZS7이 면역화에 사용되는 방법.
  10. 제7항 내지 제9항의 어느 한 항의 방법으로 얻은, 라일 질병에 대한 왁진.
  11. 하이브리도마 셀 라인 ECACC 89091302에 의해 분비된, OspA에 대한 단클론 항체 LA-2.
  12. 하이브리도마 셀 라인 ECACC 89091406에 의해 분비된, OspA에 대한 단클론 항체 LA26.1.
  13. 하이브리도마 셀 라인 ECACC 90050405에 의해 분비된, OspA에 대한 단클론 항체 LA25.1.
  14. 하이브리도마 셀 라인 ECACC 90050407에 의해 분비된, OspB에 대한 단클론 항체 LA27.1.
  15. 병원성보렐리아 버그도페리균주 ZS7, DSM 5527.
  16. 제1항 내지 제6항의 어느 한 항의 OspA에 대한 항체의 면역반응하는 항원.
  17. 제1항 내지 제6항의 어느 한 항의 OspB에 대한 항체의 면역반응하는 항원.
  18. 제16항 또는 제17항에 있어서, 항원을 암호화한 DNA 서열이 단백질 발현에 적당한 벡터상에 존재하는 항원.
  19. 제18항에 있어서, 항원을 암호화한 DNA 서열이 단백질 발현에 적당한 원핵세포의 벡터상에 존재하는 항원.
  20. 제16항 내지 제19항의 어느 한 항에 있어서, 다음 아미노산 서열 또는 이러한 서열의 면역원 에피토프를 함유한 항원.
  21. 제16항 내지 제20항의 어느 한 항에 있어서, β-갈락토시다제 융합 단백질 또는 비융합 단백질 항원.
  22. 제16항 및 제18항 내지 제21항의 어느 한 항의 항원을 암호화하고 (1) 다음에 표시된 핵산 서열, (2) 유전자 암호의 변성 범위내에서 이것에 상응하는 서열 또는 (3) 엄중한 조건하에서 (1) 및/또는 (2)의 서열과 잡종분자를 형성하는 서열을 함유한, 재조합 DNA.
  23. 제22항에 따른 재조합 DNA의 하나 이상의 복사체를 함유한 재조합 벡터.
  24. 제23항에 있어서, 원핵세포 벡터인 재조합 벡터.
  25. 제24항에 있어서, 플라즈미드인 재조합 벡터.
  26. 재조합 벡터 pZS-7/31-2 (DSM 5528).
  27. 보렐리아버그도페리 유전자 뱅크를 제1항 내지 제6항의 어느 한 항에 따른 하나 이상의 항체로 검사하고 항체 또는 항체들과의 양성 면역반응을 나타내는 클론을 분리하여, 제16항 내지 제21항의 어느 한 항의 항원을 얻는 방법.
  28. 임의로 동상적인 담체, 충전제 및 보조 물질과 함께 제16항 내지 제21항의 어느 한 항의 항체를 최소한 하나 함유하는, 라임 질병에 대한 활성 왁진.
  29. 제28항에 있어서, 항원이 유전자 공학적으로 얻어지는 왁진.
  30. 실험용 동물을 제16항 내지 제21항의 어느 한 항에 따른 항원으로 면역화시키고 OspA 및/또는 OspB에 대한 보호적인 다클론 또는 단클론 항체를 실험 동물로 부터 통상적인 방법으로 얻음에 의해 라인 질병에 대한 왁진을 얻는 방법.
  31. 제30항에 있어서, 실험용 동물이 생쥐인 방법.
  32. 병원균으로 이미 감염되었던 면역이 결핍된 실험용 동물로 부터 병원균을 얻고 병원균의 병원성을 유지시켜, 병원성보렐리아 버그도페리를 분리하고 재배양하는 방법.
  33. 제32항에 있어서, 실험용 동물이 생쥐인 방법.
  34. 제33항에 있어서, 병원성보렐리아 버그도페리이 감염된 scid 생쥐의 혈액 및/또는 관절로 부터 얻어지는 방법.
  35. 제32항 내지 제34항의 어느 한 항의 방법으로 병원성 >u>보렐리아버그도페리.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900014814A 1989-09-19 1990-09-19 라임 질병에 대한 왁진 KR100205462B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019980035375A KR100202128B1 (en) 1989-09-19 1998-08-29 Vaccine against lyme disease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE3931236 1989-09-19
DE39312364 1989-09-19
DEP39312364 1989-09-19
DE4015911A DE4015911A1 (de) 1989-09-19 1990-05-17 Impfstoff gegen die lyme-krankheit
DE40159116 1990-05-17
DEP40159116 1990-05-17

Publications (2)

Publication Number Publication Date
KR910005889A true KR910005889A (ko) 1991-04-27
KR100205462B1 KR100205462B1 (ko) 1999-07-01

Family

ID=25885304

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019900014814A KR100205462B1 (ko) 1989-09-19 1990-09-19 라임 질병에 대한 왁진
KR1019980035375A KR100202128B1 (en) 1989-09-19 1998-08-29 Vaccine against lyme disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019980035375A KR100202128B1 (en) 1989-09-19 1998-08-29 Vaccine against lyme disease

Country Status (24)

Country Link
US (6) US5178859A (ko)
EP (5) EP0418827B1 (ko)
JP (3) JP3205932B2 (ko)
KR (2) KR100205462B1 (ko)
AT (4) ATE191499T1 (ko)
AU (1) AU651560B2 (ko)
CA (1) CA2025597C (ko)
CZ (2) CZ284538B6 (ko)
DE (5) DE4015911A1 (ko)
DK (4) DK0418827T3 (ko)
ES (4) ES2145077T3 (ko)
FI (1) FI102248B (ko)
GR (3) GR3018995T3 (ko)
HK (2) HK1002405A1 (ko)
HR (1) HRP940545B1 (ko)
HU (2) HU212716B (ko)
IE (1) IE903377A1 (ko)
NO (2) NO311767B1 (ko)
NZ (1) NZ235260A (ko)
PL (2) PL170229B1 (ko)
PT (1) PT95349B (ko)
SI (1) SI9011773B (ko)
SK (3) SK283088B6 (ko)
YU (2) YU48250B (ko)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US7094391B1 (en) * 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5582829A (en) * 1990-04-05 1996-12-10 Rx Technologies, Inc. Sonicated borrelia burgdorferi vaccine
SG47447A1 (en) 1990-06-15 1998-04-17 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
ES2149759T3 (es) * 1990-07-06 2000-11-16 American Home Prod Vacuna contra la enfermedad de lyme.
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
US6872550B1 (en) 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
CA2115554A1 (en) * 1991-08-15 1993-03-04 Yves Lobet Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
WO1993008299A1 (en) * 1991-10-18 1993-04-29 Connaught Laboratories Inc. Preparation of recombinant borrelia proteins
EP0540457A1 (en) * 1991-10-22 1993-05-05 Symbicom Ab Improvements in Borrelia burgdorferi diagnosis and prophylaxis
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
US5656451A (en) * 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
US6716591B1 (en) 1993-07-30 2004-04-06 Yale University B. burgdorferi polypeptides
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US5558993A (en) * 1994-06-17 1996-09-24 The Regents Of The University Of California Cloned Borrelia burgdorferi virulence protein
GB9511909D0 (en) * 1995-06-12 1995-08-09 Microbiological Res Authority Vaccine
ATE301716T1 (de) 1996-02-21 2005-08-15 Univ Texas Vmp-ähnliche sequenzen von pathogener borrelia
DE19632862B4 (de) * 1996-08-14 2006-08-03 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe
US6458555B1 (en) * 1996-08-21 2002-10-01 Gerd Bach Cytologic method of examining mucous membranes
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
DE19740735A1 (de) * 1997-09-16 1999-03-18 Max Planck Gesellschaft Arzneimittel zur Therapie einer manifesten Lyme-Borreliose
US6306623B1 (en) 1998-02-24 2001-10-23 The University Of California Leptospiral major outer membrane protein LipL32
DE69938183T2 (de) 1998-07-31 2009-02-19 Gundersen Lutheran Medical Foundation, Inc., La Crosse Verwendungen eines borreliaziden epitops des aussermembranproteins c von borrelia burgdorferi (ospc) als impstoff
WO2000056298A2 (en) * 1999-03-19 2000-09-28 Luitpold Pharmaceuticals, Inc. Treatment of lyme disease with polysulfated glycosaminoglycan formulations
WO2000078345A1 (en) * 1999-06-21 2000-12-28 Milkhaus Laboratory, Inc. Method for treatment of lyme disease
PT1311540E (pt) 2000-08-18 2008-03-20 Univ New York State Res Found Ospa de borrelia burgdorferi modificada
EP2292762A3 (en) 2002-12-20 2012-12-12 Board of Regents, The University of Texas System VMP-like sequences of pathogenic Borrelia species and strains
UA99719C2 (ru) 2006-11-03 2012-09-25 Шеринг-Плау Лтд. Вакцина для собак против болезни лайма
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2167537A2 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
KR20120096932A (ko) * 2009-11-17 2012-08-31 아박시스, 인크. 라임병 항체의 검출을 위한 펩티드 및 방법
US8758772B2 (en) 2011-11-04 2014-06-24 Abaxis, Inc. Peptides and methods for the detection of lyme disease antibodies
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
US9610336B1 (en) * 2014-07-16 2017-04-04 Amiram Katz Immunotherapy for lyme disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4772464A (en) 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4888276A (en) 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
US4721617A (en) 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
US5034515A (en) * 1987-09-22 1991-07-23 Wisconsin Alumni Research Foundation Staphylococcal fibronectin receptor, monoclonal antibodies thereto and methods of use
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
AU7058691A (en) * 1989-12-22 1991-07-24 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologically active proteines from borrelia burgdorferi, related test kits and vaccine
SG47447A1 (en) * 1990-06-15 1998-04-17 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
ES2149759T3 (es) * 1990-07-06 2000-11-16 American Home Prod Vacuna contra la enfermedad de lyme.
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
CA2115554A1 (en) * 1991-08-15 1993-03-04 Yves Lobet Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
EP0642574B1 (en) * 1991-08-27 1998-12-09 Novo Nordisk A/S Detergent compositions
WO1993008299A1 (en) * 1991-10-18 1993-04-29 Connaught Laboratories Inc. Preparation of recombinant borrelia proteins
EP0625052A4 (en) * 1991-10-21 1995-07-19 Medimmune Inc SECRETION SIGNAL OF LIPOPROTEIN-ENCODING DNA CONTAINING BACTERIAL EXPRESSION VECTOR.

Also Published As

Publication number Publication date
ES2129551T3 (es) 1999-06-16
CZ284616B6 (cs) 1999-01-13
SK151198A3 (en) 1999-04-13
US5686267A (en) 1997-11-11
NO311767B1 (no) 2002-01-21
ATE131732T1 (de) 1996-01-15
SI9011773A (sl) 1998-04-30
SK280285B6 (sk) 1999-11-08
US5856447A (en) 1999-01-05
US5780030A (en) 1998-07-14
AU6244490A (en) 1991-03-28
SK283089B6 (sk) 2003-02-04
AU651560B2 (en) 1994-07-28
DK0633028T3 (da) 2000-04-10
EP0633313A1 (de) 1995-01-11
NO904062L (no) 1991-03-20
DK0418827T3 (da) 1996-05-06
SI9011773B (en) 2001-12-31
HUT59613A (en) 1992-06-29
DE59010888D1 (de) 1999-12-23
EP0633313B1 (de) 2000-04-05
PL170229B1 (pl) 1996-11-29
PL169804B1 (pl) 1996-09-30
PT95349A (pt) 1991-05-22
US5434077A (en) 1995-07-18
DK0633313T3 (da) 2000-07-24
NO20014624L (no) 1991-03-20
CZ97095A3 (en) 1995-09-13
IE990173A1 (en) 2000-11-01
HK1002405A1 (en) 1998-08-21
ATE175576T1 (de) 1999-01-15
JP3328644B2 (ja) 2002-09-30
KR100205462B1 (ko) 1999-07-01
FI904597A0 (fi) 1990-09-18
DE59010863D1 (de) 1999-02-25
PT95349B (pt) 1997-06-30
ATE191499T1 (de) 2000-04-15
EP0643974A1 (de) 1995-03-22
EP0418827A1 (de) 1991-03-27
JP3418171B2 (ja) 2003-06-16
DE4015911A1 (de) 1991-03-28
HRP940545A2 (en) 1997-04-30
US6613331B1 (en) 2003-09-02
SK456090A3 (en) 1999-11-08
SK283088B6 (sk) 2003-02-04
ES2145077T3 (es) 2000-07-01
EP0861664A3 (de) 1999-02-24
HU212716B (en) 1996-10-28
CA2025597A1 (en) 1991-03-20
NO904062D0 (no) 1990-09-18
NZ235260A (en) 1993-04-28
IE903377A1 (en) 1991-04-10
EP0861664A2 (de) 1998-09-02
YU177390A (sh) 1993-05-28
ES2082812T3 (es) 1996-04-01
GR3032010T3 (en) 2000-03-31
JP2001204467A (ja) 2001-07-31
DE59009978D1 (de) 1996-02-01
DE59010903D1 (de) 2000-05-11
US5178859A (en) 1993-01-12
CZ456090A3 (cs) 1998-08-12
EP0633028A1 (de) 1995-01-11
CA2025597C (en) 2004-02-03
FI102248B1 (fi) 1998-11-13
DK0643974T3 (da) 1999-09-06
ATE186646T1 (de) 1999-12-15
EP0633028B1 (de) 1999-11-17
ES2141182T3 (es) 2000-03-16
HK1013620A1 (en) 1999-09-03
HU211228A9 (en) 1995-11-28
NO315905B1 (no) 2003-11-10
GR3033675T3 (en) 2000-10-31
GR3018995T3 (en) 1996-05-31
EP0418827B1 (de) 1995-12-20
YU49370B (sh) 2005-09-19
JP2001069969A (ja) 2001-03-21
SK151098A3 (en) 1999-04-13
HRP940545B1 (en) 2000-06-30
CZ284538B6 (cs) 1998-12-16
FI102248B (fi) 1998-11-13
JP3205932B2 (ja) 2001-09-04
KR100202128B1 (en) 1999-06-15
HU905816D0 (en) 1991-03-28
YU9097A (sh) 1999-06-15
NO20014624D0 (no) 2001-09-24
JPH03209400A (ja) 1991-09-12
EP0643974B1 (de) 1999-01-13
YU48250B (sh) 1997-09-30

Similar Documents

Publication Publication Date Title
KR910005889A (ko) 라임 질병에 대한 왁진
Schaible et al. Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice.
Simon et al. Recombinant outer surface protein A from Borrelia burgdorferi induces antibodies protective against spirochetal infection in mice
Kunihiko et al. A second class of immunoglobulin other than IgM present in the serum of a cartilaginous fish, the skate, Raja kenojei: isolation and characterization
Barstad et al. Variable major proteins of Borrelia hermsii. Epitope mapping and partial sequence analysis of CNBr peptides.
Handman et al. Stage-specific, strain-specific, and cross-reactive antigens of Leishmania species identified by monoclonal antibodies
Goff et al. Identification of Babesia bovis merozoite surface antigens by using immune bovine sera and monoclonal antibodies
DE3750088T2 (de) Synthetische Polypeptide und Antikörper bezogen auf Vorzeitig-Diffus-Antigene vom Epstein-Barr-Virus.
Parham [9] Monoclonal antibodies against HLA products and their use in immunoaffinity purification
KR900701836A (ko) 신규 hiv 단백질 및 aids의 진단, 예방 또는 치료에 유용한 펩티드
Lyerly et al. Vaccination against lethal Clostridium difficile enterocolitis with a nontoxic recombinant peptide of toxin A
Barbour et al. Structural analysis of the variable major proteins of Borrelia hermsii.
CA2370493A1 (en) Peptides and assays for the diagnosis of lyme disease and compositions useful for the prevention thereof
Trueba et al. Characterization of the periplasmic flagellum proteins of Leptospira interrogans
Ikemori et al. Research note: avidity of chicken yolk antibodies to enterotoxigenic Escherichia coli fimbriae
Lew et al. Site-directed immune responses in DNA vaccines encoding ligand–antigen fusions
MX9801089A (es) Proteina hibrida que comprende epitopes estimulantes de celula auxiliar t y epitopes de celula b de la proteina de membrana externa mayor chlamydia trachomatis y su uso como vacuna.
Yarmush et al. The inheritance of antibody V regions in the rabbit: linkage of an H-chain-specific idiotype to immunoglobulin allotypes.
Kurtenbach et al. Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies
Kobayashi et al. Idetification of a second immunoglobulin in the most primitive shark, the frill shark, Chlamydoselachus anguineus
Falk et al. Skin-fixing antibody in experimental allergic encephalomyelitis
EP0467972A1 (en) Rickettsial antigens for vaccination and diagnosis
ES2323571T3 (es) Proceso para aislar selectivamente an ticuerpos igy de yema de huevo de un ave anseriforme.
May et al. Borrelia burgdorferi infection in cats in the UK
Birshtein et al. Effects of immunoglobulin structure on Fc receptor binding: a mouse myeloma variant immunoglobulin with a gamma 2b-gamma 2a hybrid heavy chain having a complete gamma 2a Fc region fails to bind to gamma 2a Fc receptors on mouse macrophages.

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040402

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee